PLGA and Eudragit-based long-acting microspheres for Parkinson's disease management
RSC Pharmaceutics · 2026 · 3 (4) · 1071-1085
DOI: 10.1039/d6pm00029k ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Deepa D. Nakmode und 4 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
A long-acting PLGA/Eudragit microsphere formulation was developed to replace frequent oral dosing for Parkinson's disease. It successfully delivered hydrophilic pramipexole, achieving sustained release for up to 18 days with excellent syringeability.
Zitieren
APA
Nakmode, D. D., Koppisetti, H., Rajapaksha, W., Song, Y., & Garg, S. (2026). PLGA and Eudragit-based long-acting microspheres for Parkinson's disease management. RSC Pharmaceutics, 3(4), 1071-1085. https://doi.org/10.1039/d6pm00029k
Vancouver
Nakmode DD, Koppisetti H, Rajapaksha W, Song Y, Garg S. PLGA and Eudragit-based long-acting microspheres for Parkinson's disease management. RSC Pharmaceutics. 2026;3(4):1071-1085. doi:10.1039/d6pm00029k
BibTeX
@article{Nakmode2026,
author = {Nakmode, Deepa D. and Koppisetti, Haripriya and Rajapaksha, Weranga and Song, Yunmei and Garg, Sanjay},
title = {PLGA and Eudragit-based long-acting microspheres for Parkinson's disease management},
journal = {RSC Pharmaceutics},
year = {2026},
volume = {3},
number = {4},
pages = {1071--1085},
doi = {10.1039/d6pm00029k}
}
EUVIMED